Clinical trials: Irritability Associated With Autism Spectrum Disorder
Irritability Associated With Autism Spectrum Disorder
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors…
- Trial name
- NCT05523895
- Testing
- Pimavanserin
- Where
- 57 sites in United States, Australia and 6 more
- Volunteers
- 237 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Autism Spectrum Disorder, Aggression
Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning.
- Conditions
- Autism Spectrum Disorder, Aggression, Irritability
- Trial name
- NCT02552147
- Testing
- Transdermal nicotine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Autism
Lurasidone Pediatric Autism Study
This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent…
- Trial name
- NCT01911442
- Testing
- Lurasidone 20 mg daily, Lurasidone
- Where
- 41 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sumitomo Pharma America, Inc.
Irritability Associated With Autism Spectrum Disorder (ASD)
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
- Trial name
- NCT04174365
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Irritability Associated With Autism Spectrum Disorder
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to…
- Trial name
- NCT05555615
- Testing
- Pimavanserin
- Where
- 48 sites in United States, Australia and 6 more
- Volunteers
- 209 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Autistic Disorder
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.
- Trial name
- NCT00198107
- Testing
- Aripiprazole, D-cycloserine
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Indiana University
Irritability Associated With Autism Spectrum Disorder
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
The purpose of this study is to evaluate the long-term safety and tolerability of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
- Trial name
- NCT04258839
- Testing
- Brexpiprazole
- Where
- 28 sites in United States
- Volunteers
- 95 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.